{"title":"Coupling Proteomics and Fermentation Technology for the Improvement of Bioactive Molecule Production Yield in Actinomycetes","authors":"G. Gallo","doi":"10.4172/2167-7972.1000E118","DOIUrl":null,"url":null,"abstract":"Copyright: © 2013 Gallo. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Most bioactive molecules (like anticancers, antitumors, antibiotics, immunosuppressants, insecticidals, antivirals, herbicidals, antifungals) with valuable industrial and market value are naturally produced by actinomycetes [1-4], Gram-positive filamentous bacteria widespread in both terrestrial and aquatic environments [5,6]. Out of thousands of bioactive molecules, also known as secondary metabolites since they are not essential for actinomycete growth in standard laboratory condition at least, more than 50% are synthesised by strains of Streptomyces genus [4]. Despite the cellular and ecological role of secondary metabolites is still debated [3,7], microbial fermentation is widely exploited to produce these compounds at industrial level. Although they have many different activities and range within a vast chemical complexity and diversity, there are two main common issues which could be addressed for the establishment of a cost-effective microbial fermentation process:","PeriodicalId":12351,"journal":{"name":"Fermentation Technology","volume":"159 1","pages":"1-2"},"PeriodicalIF":0.0000,"publicationDate":"2013-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fermentation Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2167-7972.1000E118","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
提高放线菌生物活性分子产率的蛋白质组学与发酵耦合技术
版权所有:©2013 Gallo。这是一篇根据知识共享署名许可协议发布的开放获取文章,该协议允许在任何媒体上不受限制地使用、分发和复制,前提是要注明原作者和来源。大多数具有工业和市场价值的生物活性分子(如抗癌、抗肿瘤、抗生素、免疫抑制剂、杀虫剂、抗病毒药物、除草剂、抗真菌药物)都是由放线菌自然产生的[1-4],放线菌是广泛存在于陆地和水生环境中的革兰氏阳性丝状细菌[5,6]。在成千上万的生物活性分子中,也被称为次级代谢物,因为它们至少在标准实验室条件下对放线菌的生长不是必需的,超过50%是由链霉菌属[4]菌株合成的。尽管次生代谢物的细胞和生态作用仍存在争议[3,7],但微生物发酵已被广泛用于工业生产这些化合物。尽管它们在巨大的化学复杂性和多样性中具有许多不同的活动和范围,但要建立具有成本效益的微生物发酵过程,可以解决两个主要的共同问题:
本文章由计算机程序翻译,如有差异,请以英文原文为准。